Mercaptopurine-Modified miRNA Mimics for AML Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for acute myeloid leukemia (AML) are inadequate, particularly for elderly patients, with high toxicity and limited survival benefits, necessitating the development of new treatments with reduced toxicity and improved survival outcomes.
Innovation Solution
A composition containing miRNA mimics with adenine bases replaced by 6-mercaptopurine (6-MP) and 5-fluorouracil (5-FU) is used to target cancer cells, specifically using miR-15a, miR-16, miR-129, miR-194, miR-192, miR-139, or miR-140, administered via various routes to effectively kill cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapeutic approaches (anthracycline and cytarabine) are used to treat AML, then cancer cell killing efficacy is improved, but toxicity increases and elderly patients cannot tolerate the treatment
Solution Approach 1:
The patent modifies the chemical structure of mercaptopurine by incorporating it into miRNA molecules, changing the parameter of molecular composition. This creates a novel therapeutic agent that maintains anticancer activity while reducing toxicity, allowing elderly patients to tolerate treatment who previously could not withstand conventional chemotherapy
Solution Approach 2:
The patent creates a composite therapeutic molecule by integrating mercaptopurine (6-MP) within miRNA structures. This composite approach combines the gene-silencing capability of miRNA with the anticancer properties of mercaptopurine, producing a dual-function agent that achieves both selective cancer cell targeting and reduced systemic toxicity
2Reliability
If intensive chemotherapy is used to improve survival outcomes in AML, then cancer cell destruction is enhanced, but elderly patients become ineligible for treatment
Solution Approach 1:
The patent alters the therapeutic parameter profile by using modified miRNA-6MP molecules that exhibit different toxicity characteristics compared to conventional chemotherapy. This parameter change expands the eligible patient population to include elderly individuals who were previously excluded from curative-intent treatment due to age-related tolerance limitations
3Productivity
If conventional chemotherapy agents are administered, then rapid cell proliferation is inhibited, but treatment effectiveness is limited in elderly populations
Solution Approach 1:
The patent changes the pharmacological parameters of the therapeutic agent by using modified miRNA-6MP molecules with altered stability, distribution, and cellular uptake characteristics. These parameter modifications enable effective inhibition of cell proliferation in elderly patients while maintaining an acceptable safety profile, overcoming the limitations of conventional chemotherapy in this population
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified miRNA mimics demonstrate enhanced efficacy in inhibiting cancer cell viability, particularly at lower concentrations, offering a promising therapeutic option with reduced toxicity for AML and other leukemias.
Implementation Method 1
Individual miRNAs can inhibit the expression of many different target genes through imperfect base pairing to their 3′ untranslated region
Implementation Method 2
Mercaptopurine ('6-MP') is an antimetabolic agent that inhibits DNA and RNA synthesis, resulting in the killing of rapidly proliferating cells
Data Source
AI summary
A composition that includes a micro-RNA mimic containing one or more adenine bases in which at least one adenine base is replaced by 6-mercaptopurine. Also provided is a method for killing a cancer cell by contacting it with a composition that includes a micro-RNA mimic containing 6-mercaptopurine and 5-fluorouracil in which the micro-RNA mimic is miR-15a, miR-16, miR-129, miR-194, miR-192, miR-139, miR-140, or miR-145. Further, disclosed is a method for treating cancer by administering a composition containing a micro-RNA mimic having a guide strand and a passenger strand in which at least one adenine base in the guide strand or the passenger strand has been replaced by 6-mercaptopurine.